Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Current Deferred Revenue (2023 - 2025)

Telix Pharmaceuticals has reported Current Deferred Revenue over the past 3 years, most recently at $402000.0 for Q4 2025.

  • Quarterly Current Deferred Revenue fell 94.53% to $402000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $402000.0 through Dec 2025, down 94.53% year-over-year, with the annual reading at $402000.0 for FY2025, 94.23% down from the prior year.
  • Current Deferred Revenue was $402000.0 for Q4 2025 at Telix Pharmaceuticals, down from $7.4 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $7.4 million in Q4 2024 and troughed at $402000.0 in Q4 2025.
  • The 3-year median for Current Deferred Revenue is $7.2 million (2023), against an average of $5.0 million.
  • Year-over-year, Current Deferred Revenue grew 2.77% in 2024 and then tumbled 94.53% in 2025.
  • A 3-year view of Current Deferred Revenue shows it stood at $7.2 million in 2023, then increased by 2.77% to $7.4 million in 2024, then tumbled by 94.53% to $402000.0 in 2025.
  • Per Business Quant, the three most recent readings for TLX's Current Deferred Revenue are $402000.0 (Q4 2025), $7.4 million (Q4 2024), and $7.2 million (Q4 2023).